OSU K12 Training Grant for Clinical Faculty Investigators

OSU K12 临床教师研究人员培训补助金

• 批准号: 8684456
• 负责人: JOHN C. BYRD
• 金额: $ 80.83万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-09 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8684456
• 关键词: Applied Research; Basic Science; Clinical; Clinical Investigator; Clinical Oncology Supplement (K12); Clinical Research; Comprehensive Cancer Center; Critiques; Doctor of Philosophy; Education; Ensure; Faculty; Fellowship; Financial Support; Goals; Grant; Hematology; Individual; Investigation; Laboratories; Malignant Neoplasms; Medical Oncology; Medicine; Mentors; Minority; Nursing Faculty; Ohio; Patients; Peer Review; Phase II/III Trial; Program Evaluation; Radiation Oncology; Recruitment Activity; Research; Research Personnel; Resources; SECTM1 gene; Scientist; Solid Neoplasm; Surgical Oncology; Teacher Professional Development; Therapeutic; Training; Training Programs; Training and Education; Translational Research; Universities; Woman; base; cancer prevention; career; career development; drug development; interest; oncology; professor; programs; success; survivorship

DESCRIPTION (provided by applicant): The goal of this proposal is to mentor and effectively train faculty-level investigators in basic science and/or clinically-oriented approaches to translational research. Implementation of this K12 award for the career development of basic translational scientists (PhD, DVM, and MD) and clinical translational scientists (MD and MD/PhD) in Hematologic Oncology, Medical Oncology, Radiation Oncology and Surgical Oncology will ensure a cadre of highly-trained individuals dedicated to drug development as well as cancer prevention, control, and survivorship research. This K12 renewal from The Ohio State University Comprehensive Cancer Center (OSUCCC) continues its training focus on early drug development along with larger phase II/III trials, but now also extends to cancer prevention, control and survivorship research based on the previous critique. Focus on recruitment of scholars with interest in common solid tumors is also emphasized, as suggested. The OSUCCC is clearly dedicated to research education and providing outstanding training and mentoring opportunities to promising junior faculty. The OSU Divisions of Hematology, Medical Oncology, Radiation Oncology, and Surgical Oncology each have robust fellowship training programs that are continuously recruiting new junior faculty to facilitate expansion of our cancer program. Recruitment from other fellowship training programs also occurs, with particular focus on identification of women, minorities and people of different ethnic backgrounds to increase diversity. This K12 grant fills an important need by extending research education, training and mentoring to junior faculty interested in developing academic careers focused on clinical research. Moreover, it will be the only OSUCCC training program solely dedicated to career development in cancer at the faculty level, and therefore has no overlap with any of the OSU T32 training grants focused on fellows. This strategy will ensure continuity in training and provide individuals with the ability to become independent clinical investigators. Based upon the overall strength and direction of the OSUCCC, as demonstrated by its recent peer review score of 12 (exceptional), financial support of this K12 by OSUCCC, financial support by different Divisions and Departments, and breadth of resources available at OSU, this K12 proposal seeks to train primarily two types of assistant professors. The first group includes MD or PhD faculty (basic translational trainees) who have outstanding basic science training and desire to pursue laboratory investigation related to applied research in experimental therapeutics as well as cancer prevention, control, and survivorship. The second group includes MD or MD/PhD faculty (clinical translational trainees) who pursue patient-related research in clinically-focused experimental therapeutics and cancer prevention, control, or survivorship. Training plans tailored to each of these individual trainees will facilitate their success, with inclusion of a roust evaluation program to assess the success of the K12. This is best demonstrated by all of the current and past K12 scholars remaining in academic medicine and moving forward as independent clinical investigators.

描述（由申请人提供）：本提案的目标是指导和有效地培训基础科学和/或临床导向的方法转化研究的院系级调查人员。K12奖的实施是为了促进血液肿瘤学、内科肿瘤学、放射肿瘤学和外科肿瘤学领域的基础转化科学家（PhD、DVM和MD）和临床转化科学家（MD和MD/PhD）的职业发展，这将确保一支训练有素的人员队伍致力于药物开发以及癌症预防、控制和生存研究。俄亥俄州州立大学综合癌症中心（OSUCCC）的K12更新继续其早期药物开发沿着更大的II/III期试验的培训重点，但现在也扩展到癌症预防，控制和生存研究的基础上以前的批评。重点招聘学者的兴趣在常见的实体瘤也强调，如建议。OSUCCC显然致力于研究教育，并为有前途的初级教师提供出色的培训和指导机会。OSU血液学，内科肿瘤学，放射肿瘤学和外科肿瘤学部门都有强大的奖学金培训计划，不断招募新的初级教师，以促进我们的癌症计划的扩展。还从其他奖学金培训方案中招聘人员，特别注重确定妇女、少数民族和不同种族背景的人，以增加多样性。这K12赠款填补了一个重要的需求，通过扩展研究教育，培训和指导感兴趣的发展学术生涯专注于临床研究的初级教师。此外，它将是唯一一个专门致力于癌症职业发展的OSUCCC培训计划，因此与OSU T32培训赠款没有重叠。这一战略将确保培训的连续性，并为个人提供成为独立临床研究者的能力。基于OSUCCC的整体实力和方向，正如其最近的同行评审得分12（例外），OSUCCC对K12的财政支持，不同部门和部门的财政支持以及OSU可用资源的广度所证明的那样，K12的建议旨在主要培养两种类型的助理教授。第一组包括医学博士或博士教师（基本的翻译实习生），他们具有出色的基础科学培训，并希望从事与实验治疗学以及癌症预防，控制和生存相关的应用研究的实验室调查。第二组包括医学博士或医学博士/博士教师（临床翻译实习生），他们在以临床为重点的领域从事与患者相关的研究。 实验疗法和癌症预防、控制或存活。为每个学员量身定制的培训计划将促进他们的成功，包括一个roust评估计划，以评估K12的成功。这是最好的证明，所有当前和过去的K12学者留在学术医学和前进作为独立的临床研究者。